Arcus Biosciences, Inc. (RCUS)

Price$23.19

Value ScoreD

Growth ScoreC

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)-19.07%

Price vs S&P 500 (4W)-8.55%

VGM Score51.55

Market Capitalization$2.92B

All Metrics

Book Value / Share (Quarterly)$4.18

P/TBV (Annual)1.60x

Revenue Growth (3Y)30.16%

Cash Flow / Share (Quarterly)$-3.90

Price vs S&P 500 (YTD)-10.84%

Net Profit Margin (TTM)-156.36%

EPS (TTM)$-3.18

10-Day Avg Trading Volume1.05M

EPS Excl Extra (TTM)$-3.18

Revenue Growth (5Y)26.09%

EPS (Annual)$-3.29

ROI (Annual)-48.36%

Net Profit Margin (5Y Avg)-147.92%

Cash / Share (Quarterly)$6.55

Revenue Growth QoQ (YoY)26.92%

ROA (Last FY)-30.99%

Revenue Growth TTM (YoY)-15.12%

EBITD / Share (TTM)$-3.41

ROE (5Y Avg)-43.02%

Operating Margin (TTM)-168.64%

Cash Flow / Share (Annual)$-3.86

P/B Ratio5.57x

P/B Ratio (Quarterly)5.17x

Net Income / Employee (Annual)$-587,400

EV / Revenue (TTM)11.93x

ROA (TTM)-35.27%

EV / EBITDA (TTM)34.59x

EPS Incl Extra (Annual)$-3.29

Current Ratio (Annual)4.36x

Quick Ratio (Quarterly)3.97x

3-Month Avg Trading Volume1.15M

52-Week Price Return140.81%

Revenue / Employee (TTM)$392,700

Tangible BV / Share (Quarterly)$6.95

P/S Ratio (Annual)11.81x

Asset Turnover (Annual)0.22x

52-Week High$28.72

Operating Margin (5Y Avg)-162.13%

EPS Excl Extra (Annual)$-3.29

CapEx CAGR (5Y)-8.39%

Tangible BV CAGR (5Y)33.69%

26-Week Price Return-11.15%

Quick Ratio (Annual)4.32x

13-Week Price Return4.41%

Total Debt / Equity (Annual)0.16x

Current Ratio (Quarterly)4.04x

Enterprise Value$2.82B

Revenue / Share Growth (5Y)10.21%

Asset Turnover (TTM)0.23x

Book Value / Share Growth (5Y)-8.18%

Revenue / Employee (Annual)$411,000

Pretax Margin (Annual)-142.91%

Cash / Share (Annual)$7.83

3-Month Return Std Dev55.95%

Net Income / Employee (TTM)$-614,000

ROE (Last FY)-55.94%

EPS Basic Excl Extra (Annual)$-3.29

P/FCF (TTM)116.67x

Receivables Turnover (TTM)16.86x

Total Debt / Equity (Quarterly)0.19x

EPS Incl Extra (TTM)$-3.18

Receivables Turnover (Annual)12.05x

ROI (TTM)-58.25%

P/S Ratio (TTM)12.36x

Pretax Margin (5Y Avg)-146.54%

Revenue / Share (Annual)$2.30

Tangible BV / Share (Annual)$9.01

Price vs S&P 500 (52W)116.44%

Year-to-Date Return-2.69%

5-Day Price Return-9.66%

EPS Normalized (Annual)$-3.29

ROA (5Y Avg)-20.03%

Net Profit Margin (Annual)-142.91%

Month-to-Date Return-8.48%

Cash Flow / Share (TTM)$-3.91

EBITD / Share (Annual)$-3.50

Operating Margin (Annual)-156.28%

LT Debt / Equity (Annual)0.16x

ROI (5Y Avg)-40.46%

LT Debt / Equity (Quarterly)0.19x

EPS Basic Excl Extra (TTM)$-3.18

P/TBV (Quarterly)2.02x

P/B Ratio (Annual)4.67x

Pretax Margin (TTM)-156.36%

Book Value / Share (Annual)$5.04

Price vs S&P 500 (13W)-3.84%

Beta0.85x

P/FCF (Annual)6.75x

Revenue / Share (TTM)$1.88

ROE (TTM)-68.97%

52-Week Low$7.91

vGradeD

gGradeC

mGradeB

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-1.02est. -0.89

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.11

4.06

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
RCUSArcus Biosciences, Inc.	D	C	B	$23.19
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Arcus Biosciences is a late clinical-stage biopharmaceutical company developing differentiated molecular therapies for cancer and inflammatory and autoimmune diseases. The company's pipeline includes several investigational drug candidates designed to address unmet medical needs in these therapeutic areas.